title: Current and next generation influenza vaccines: Formulation and production strategies.
abstract: Vaccination is the most effective method to prevent influenza infection. However, current influenza vaccines have several limitations. Relatively long production times, limited vaccine capacity, moderate efficacy in certain populations and lack of cross-reactivity are important issues that need to be addressed. We give an overview of the current status and novel developments in the landscape of influenza vaccines from an interdisciplinary point of view. The feasibility of novel vaccine concepts not only depends on immunological or clinical outcomes, but also depends on biotechnological aspects, such as formulation and production methods, which are frequently overlooked. Furthermore, the next generation of influenza vaccines is addressed, which hopefully will bring cross-reactive influenza vaccines. These developments indicate that an exciting future lies ahead in the influenza vaccine field.
authors.affiliation: Intravacc (Institute for Translational Vaccinology), Bilthoven, The Netherlands; Division of Drug Delivery and Technology, Leiden Academic Centre for Drug Research, Leiden University, The Netherlands.
authors.forename: Peter C
authors.initials: PC
authors.lastname: Soema
authors.affiliation: Intravacc (Institute for Translational Vaccinology), Bilthoven, The Netherlands; FluConsult, Noordwijk, The Netherlands.
authors.forename: Ronald
authors.initials: R
authors.lastname: Kompier
authors.affiliation: Intravacc (Institute for Translational Vaccinology), Bilthoven, The Netherlands. Electronic address: jean-pierre.amorij@intravacc.nl.
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Amorij
authors.affiliation: Intravacc (Institute for Translational Vaccinology), Bilthoven, The Netherlands; Division of Drug Delivery and Technology, Leiden Academic Centre for Drug Research, Leiden University, The Netherlands.
authors.forename: Gideon F A
authors.initials: GF
authors.lastname: Kersten
mesh_terms: D000276:Adjuvants, Immunologic / Q000737:chemistry; D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D002626:Chemistry, Pharmaceutical; D015195:Drug Design; D004345:Drug Industry / Q000379:methods*; D006801:Humans; D007252:Influenza Vaccines / Q000737:chemistry* / Q000276:immunology*; D009975:Orthomyxoviridae / Q000276:immunology; D014613:Vaccines, Attenuated / Q000737:chemistry / Q000276:immunology; D014614:Vaccines, Synthetic / Q000737:chemistry / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D007252:Influenza Vaccines; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic
keywords: Influenza vaccine limitations; Influenza vaccines; Novel influenza vaccines; Universal influenza vaccine; Vaccine formulation; Vaccine production